Key Takeaways
- Artiva's lead candidate AlloNK, when combined with rituximab, has shown a 62% complete response rate in non-Hodgkin lymphoma patients and can be administered in an outpatient setting, unlike CAR-T therapies that require hospitalization.
- The company's manufacturing process can generate over 4,000 treatment vials from a single umbilical cord at approximately $1,000 cost per vial, potentially making cell therapy more accessible than current CAR-T approaches.
- Following promising academic results using CAR-T for lupus, Artiva is expanding into autoimmune diseases with clinical trials in SLE and lupus nephritis, leveraging NK cells' natural behavior and short persistence for "immune reset."
In the maturing landscape of cell therapy, Artiva Biotherapeutics stands out for its unique approach: using un-engineered natural killer
Under the leadership of Fred Aslan, the San Diego-based company hopes its approach will make cell therapy more accessible to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?